Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

The earnings call summary and Q&A section indicate positive sentiment overall. Strong product launches and business updates, such as Tryptyr and Unity, are expected to drive growth. While there are challenges in international markets like China, management is confident about their strategies. The guidance for 2026 suggests optimism, with potential outperformance from new products. Despite some uncertainties in the IOL market, the company's focus on innovation and expanding its portfolio supports a positive outlook. The stock is likely to see a positive movement in the next two weeks, given these factors.
The earnings call presents a mixed outlook. While there is optimism about new products, market expansion, and margin improvements, there are significant challenges such as tariff impacts, competition, and cautious guidance. The Q&A highlights management's cautiousness and lack of specific guidance, which could limit positive sentiment. The overall sentiment is neutral, as positive factors are offset by uncertainties and competitive pressures.
The earnings call summary presents a mixed picture. While there is growth in certain areas like the ocular health sales and free cash flow, there are also concerns such as the decline in core operating margin and the impact of tariffs. The Q&A section reveals management's cautious outlook, with no specific guidance for 2026 and challenges in the global IOL market. The strategic acquisitions and product launches offer potential, but uncertainties remain. Overall, the sentiment is neutral, with balanced positive and negative factors.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.